


GYKI 53655 hydrochloride

Cat. No.:	HY-103228
CAS No.:	143692-48-2
Molecular Formula:	C ₁₉ H ₂₁ ClN ₄ O ₃
Molecular Weight:	388.85
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 160 mg/mL (411.47 mM)
 H₂O : 8 mg/mL (20.57 mM; Need ultrasonic and warming)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.5717 mL	12.8584 mL	25.7169 mL
	5 mM	0.5143 mL	2.5717 mL	5.1434 mL	
	10 mM	0.2572 mL	1.2858 mL	2.5717 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

GYKI 53655 (LY300168) hydrochloride is an α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.

IC₅₀ & Target

AMPA^[1]

In Vitro

GYKI 53655 (LY300168) hydrochloride inhibits α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) (10 μ M)-induced responses with IC₅₀ value of 5.9±0.1 μ M. GYKI 53655 hydrochloride inhibits AMPA (10 μ M) responses in recombinant G1uR4 expressing HEK293 cells with IC₅₀ value of 4.6±0.4 μ M. Using 3 μ M cyclothiazide the inhibition produced by GYKI 53655 hydrochloride is 79±2% (n=4 cells). GYKI 53655 hydrochloride produces only small inhibitions of kainate-induced currents at 30 μ M and inhibits kainate-induced currents at a concentration of 100 μ M by 12±2 (n=4) and 18±4 (n=4), respectively. GYKI 53655 hydrochloride inhibits AMPA receptor-mediated responses in cerebella Purkinje neurons with an IC₅₀ value of 1.5±0.1 μ M^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GYKI 53655 hydrochloride (4 mg/kg) is found to have a short-lasting depressant effect on neuronal responses to iontophoretic α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), with a half-recovery time of approximately 7

min. GYKI 53655 hydrochloride (4 and 8 mg/kg) substantially depresses or completely abolishes AMPA responses. Results demonstrate the dose-dependence of GYKI 53655 hydrochloride (2 to 8 mg/kg) in depressing responses to AMPA. At the highest doses tested, GYKI 53655 hydrochloride reduces AMPA responses to a comparable degree^[2]. Tonic fit and death are completely prevented by GYKI 53655 hydrochloride at dose over 5.0 mg/kg. The ED₅₀ value of GYKI 53655 hydrochloride is 2.2 mg/kg i.p. The maximal effects of GYKI 53655 hydrochloride lasts 3 h then the exit inhibition effect of GYKI 53655 hydrochloride falls to 20% 1 h later^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

Whole-cell voltage clamp recordings are made from single cells with use of the tight seal whole cell configuration of the patch-clamp technique. Experiments are performed at room temperature (20 to 22°C) and recorded on an amplifier. GYKI 53655 hydrochloride application is via a series of perfusion lines to a multi-barrelled applicator and exchange of solutions under the present recording conditions is approximately 100 msec. For the acutely isolated cerebella Purkinje neurons, GYKI 53655 hydrochloride application is by bath perfusion and occurs within approximately 15 sec. Curve fitting to data points is based upon the equation $y = 100(D^n / (D^n + IC_{50}^n))$, where the slope of the line n is fixed to a value of 1 and D is the antagonist concentration. Statistical significance is determined by one-way ANOVA followed by Student-Newman-Keuls test^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[2]

Experiments are performed on 27 male Wistar rats (260 to 350 g). Briefly, rats are anaesthetized with halothane in O₂ and tracheal, carotid and jugular cannulae are inserted. The lumbo-thoracic spinal cord is exposed and cut at T9-T11 and the animal is prepared for extracellular recordings of single dorsal horn neurone action potentials. Anaesthesia after surgery is maintained with α -chloralose. Jugular cannulae are inserted. GYKI 53655 hydrochloride is administered intravenously. The effect of GYKI 53655 hydrochloride is expressed quantitatively as percentages of control excitatory amino acids (EAA) responses, where control is taken as the mean of the last 3 pre-drug counts; mean values \pm s.e. mean are indicated. No corrections for spontaneous activity are made^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Bleakman D, et al. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. *Neuropharmacology*. 1996;35(12):1689-702.
- [2]. Chizh BA, et al. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord. *Br J Pharmacol*. 1994 Jul;112(3):843-6.
- [3]. Szabados T, et al. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. *Brain Res Bull*. 2001 Jun;55(3):387-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA